FDA Approves Yesintek: A New Biosimilar to Stelara

The Indian Pharma16 Dec, 2024Health

The U.S. Food and Drug Administration (FDA) has granted approval for Yesintek, a groundbreaking biosimilar to Stelara (ustekinumab). Yesintek is designed to provide a cost-effective alternative for the treatment of chronic inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This marks a significant step forward in expanding access to vital biologic therapies.